Roche / Genentech never release much in terms of deal size but looks like they've gone with the safe bet on "undruggable targets" with small molecules & DICE.
https://www.fiercebiotech.com/biotech/genentech-dice-ally-to-go-after-hard-to-drug-targets
Roche also went on the same day with Confo - neurological disorders is outside of PYC's target market but again with small molecules although g-protein receptors where in the past an area of interest for PYC.
https://www.fiercebiotech.com/biote...elopmental-disorder-drug-discovery-pact-confo
Maybe one day ......
Ann: Phylogica Strategic Update - Pivot to Platform, page-41
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.30 |
Change
0.025(1.97%) |
Mkt cap ! $755.3M | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.31 | $1.27 | $258.9K | 200.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3158 | $1.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.30 | 27132 | 2 |
View Market Depth
| Last trade - 16.10pm 30/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |